rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Javier Rodriguez

Officer

Company insider

Files Form 4 as: Officer, BioXcel Therapeutics.

In numbers

Trades disclosed
88
Buys
0
Sells
8
Bought
$0
Sold
$89K
Companies
1
Companies where not an officer
0
First trade
22 Feb 2021
Last trade
15 Jun 2026
Last filed
17 Jun 2026

Companies traded

Where they are an officer
BioXcel TherapeuticsOfficer · Biotechnology · last 15 Jun 20260 buys · 8 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
10Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
15 Jun 2026filed 17 Jun 2026BioXcel TherapeuticsBiotechnologySEC FORM 4 Code M—35filing
15 Jun 2026filed 17 Jun 2026BioXcel Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—35 at $0.00filing
15 Jun 2026filed 17 Jun 2026BioXcel Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—35 at $0.00filing
15 Jun 2026filed 17 Jun 2026BioXcel TherapeuticsBiotechnologySEC FORM 4 Code M—35filing
20 May 2026filed 22 May 2026BioXcel TherapeuticsBiotechnologySEC FORM 4 Sold$7,1116,560 at $1.08filing
20 May 2026filed 22 May 2026BioXcel TherapeuticsBiotechnologySEC FORM 4 Sold$7,0856,560 at $1.08filing
4 May 2026filed 22 May 2026BioXcel TherapeuticsBiotechnologySEC FORM 4 Code M—17,500filing
4 May 2026filed 22 May 2026BioXcel Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—17,500 at $0.00filing
4 May 2026filed 22 May 2026BioXcel Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—17,500 at $0.00filing
4 May 2026filed 22 May 2026BioXcel TherapeuticsBiotechnologySEC FORM 4 Code M—17,500filing
1 May 2026filed 7 May 2026BioXcel TherapeuticsBiotechnologySEC FORM 4 Code M—9,000filing
1 May 2026filed 7 May 2026BioXcel Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—9,000 at $0.00filing
1 May 2026filed 7 May 2026BioXcel Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—9,000 at $0.00filing
1 May 2026filed 7 May 2026BioXcel TherapeuticsBiotechnologySEC FORM 4 Code M—9,000filing
15 Mar 2026filed 16 Mar 2026BioXcel TherapeuticsBiotechnologySEC FORM 4 Code M—35filing
15 Mar 2026filed 16 Mar 2026BioXcel Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—35 at $0.00filing
15 Mar 2026filed 16 Mar 2026BioXcel Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—35 at $0.00filing
15 Mar 2026filed 16 Mar 2026BioXcel TherapeuticsBiotechnologySEC FORM 4 Code M—35filing
14 Mar 2026filed 16 Mar 2026BioXcel TherapeuticsBiotechnologySEC FORM 4 Code M—33filing
14 Mar 2026filed 16 Mar 2026BioXcel Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—33 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Health Care8

Buys in green, sells in red, by the company’s sector.

Related people

Susan E. AtkinsDirector · Director at BioXcel Therapeutics, filing Form 4 there in the last year
Frank YoccaChief Scientific Officer · Chief Scientific Officer at BioXcel Therapeutics, filing Form 4 there in the last year
Vimal MehtaCEO and President · CEO and President at BioXcel Therapeutics, filing Form 4 there in the last year
Richard I. SteinhartDirector · Chief Financial Officer at BioXcel Therapeutics, filing Form 4 there in the last year
Michael Patrick MillerDirector · Director at BioXcel Therapeutics, filing Form 4 there in the last year